Literature DB >> 16646070

Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus.

Jill E Koshiol1, Jane C Schroeder, Denise J Jamieson, Stephen W Marshall, Ann Duerr, Charles M Heilig, Keerti V Shah, Robert S Klein, Susan Cu-Uvin, Paula Schuman, David Celentano, Jennifer S Smith.   

Abstract

Persistent infection with high-risk human papillomavirus (HPV) is central to cervical carcinogenesis. Certain high-risk types, such as HPV16, may be more persistent than other HPV types, and type-specific HPV persistence may differ by HIV serostatus. This study evaluated the association between HPV type and clearance of HPV infections in 522 HIV-seropositive and 279 HIV-seronegative participants in the HIV Epidemiology Research Study (HERS, United States, 1993-2000). Type-specific HPV infections were detected using MY09/MY11/HMB01-based PCR and 26 HPV type-specific probes. The estimated duration of type-specific infections was measured from the first HPV-positive visit to the first of two consecutive negative visits. Hazard ratios (HRs) and 95% confidence intervals (CIs) for HPV clearance were calculated using Cox models adjusted for study site and risk behavior (sexual or injection drugs). A total of 1,800 HPV infections were detected in 801 women with 4.4 years median follow-up. HRs for clearance of HPV16 and related types versus low-risk HPV types were 0.79 (95% CI: 0.64-0.97) in HIV-positive women and 0.86 (95% CI: 0.59-1.27) in HIV-negative women. HRs for HPV18 versus low-risk types were 0.80 (95% CI: 0.56-1.16) and 0.57 (95% CI: 0.22-1.45) for HIV-positive and -negative women, respectively. HPV types within the high-risk category had low estimated clearance rates relative to low-risk types, but HRs were not substantially modified by HIV serostatus. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16646070     DOI: 10.1002/ijc.22015

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Clinical parameters essential to methodology and interpretation of mucosal responses.

Authors:  Brenna L Anderson; Susan Cu-Uvin
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

Review 2.  [Human papilloma virus-induced disease in HIV-positive patients].

Authors:  R Wienecke; N H Brockmeyer; A Kreuter
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

3.  The Role of Chlamydia trachomatis in High-Risk Human Papillomavirus Persistence Among Female Sex Workers in Nairobi, Kenya.

Authors:  Nadja Vielot; Michael G Hudgens; Nelly Mugo; Michael Chitwa; Joshua Kimani; Jennifer Smith
Journal:  Sex Transm Dis       Date:  2015-06       Impact factor: 2.830

4.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

Review 5.  How will HPV vaccines affect cervical cancer?

Authors:  Richard Roden; T-C Wu
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

6.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

7.  Parametric frailty models for clustered data with arbitrary censoring: application to effect of male circumcision on HPV clearance.

Authors:  Xiangrong Kong; Kellie J Archer; Lawrence H Moulton; Ronald H Gray; Mei-Cheng Wang
Journal:  BMC Med Res Methodol       Date:  2010-05-06       Impact factor: 4.615

Review 8.  HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Authors:  Luciano Mariani; Aldo Venuti
Journal:  J Transl Med       Date:  2010-10-27       Impact factor: 5.531

Review 9.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.

Authors:  Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2008-05-15       Impact factor: 4.897

10.  Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination.

Authors:  Helen Trottier; Salaheddin Mahmud; José Carlos M Prado; Joao S Sobrinho; Maria C Costa; Thomas E Rohan; Luisa L Villa; Eduardo L Franco
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.